eISSN: 3023-6940
The New Journal of Urology
  • Home
  • Effects of Antiplatelet Therapy Use on the Diagnosis of Bladder Cancer: Is it a Facilitator or Complicator?

Article Tools

Related Subjects

E-SUBMISSION

Original Research

Effects of Antiplatelet Therapy Use on the Diagnosis of Bladder Cancer: Is it a Facilitator or Complicator?


1 Sakarya University, Faculty of Medicine, Department of Urology, Sakarya, Turkey 
2 Sakarya University, Training and Research Hospital, Sakarya, Turkey


DOI : 10.33719/yud.595945
New J Urol. 2020; 15-(2): 109-114
Abstract

Abstract

Objective: Haematuria, which is the most common presenting symptom in bladder cancer (BCa), may also occur with the effect of some me- dications. The aim of this study was to evaluate the role of antiplatelet (AP) drugs in the diagnosis of BCa.

Material and Methods: Patients who app- lied to our urology clinic between January 2013 and December 2018 and underwent transureth- ral resections (TURs) for primary BCa were re- viewed retrospectively. Patients were divided into 2 groups according to AP drug use (group 1: no AP therapy, group 2: recieving AP therapy). The groups were compared in terms of demographic data, complaint of admission, smoking status, tu- mor size, multifocality, pathologic stage and grade, and BCa risk group.

Results: A total of 290 patients, 233 in Group 1 and 57 in Group 2, were included in the study. The mean age of the patients was 68.69 ± 9.48 ye- ars and 246 of (84.8%) patients were male. There was no statistically significant difference between groups in terms of age, sex, presenting symptom, smoking status, tumor size, multifocality, patho- logical stage and grade and BCa risk groups.

Conclusion: According to our results, AP drug use in BCa was found to have no effect on pathologic results, tumor size, multifocality and presenting symptom at the first diagnosis and can not be conclude that cause early or delayed diag- nosis in BCa.

Keywords: Antiplatelet; bladder cancer; early diagnosis; haematuria; transurethral resection
 

Abstract

Objective: Haematuria, which is the most common presenting symptom in bladder cancer (BCa), may also occur with the effect of some me- dications. The aim of this study was to evaluate the role of antiplatelet (AP) drugs in the diagnosis of BCa.

Material and Methods: Patients who app- lied to our urology clinic between January 2013 and December 2018 and underwent transureth- ral resections (TURs) for primary BCa were re- viewed retrospectively. Patients were divided into 2 groups according to AP drug use (group 1: no AP therapy, group 2: recieving AP therapy). The groups were compared in terms of demographic data, complaint of admission, smoking status, tu- mor size, multifocality, pathologic stage and grade, and BCa risk group.

Results: A total of 290 patients, 233 in Group 1 and 57 in Group 2, were included in the study. The mean age of the patients was 68.69 ± 9.48 ye- ars and 246 of (84.8%) patients were male. There was no statistically significant difference between groups in terms of age, sex, presenting symptom, smoking status, tumor size, multifocality, patho- logical stage and grade and BCa risk groups.

Conclusion: According to our results, AP drug use in BCa was found to have no effect on pathologic results, tumor size, multifocality and presenting symptom at the first diagnosis and can not be conclude that cause early or delayed diag- nosis in BCa.

Keywords: Antiplatelet; bladder cancer; early diagnosis; haematuria; transurethral resection
 

Abstract

Abstract

Objective: We aimed to determine the relati- onship between vitamin D levels and benign pros- tate hyperplasia (BPH) related lower urinary tract symptoms (LUTS) in men over 40 years of age.

Material and Methods: The study was con- ducted prospectively between January and April 2019 and included 48 patients who presented to the outpatient clinic with lower urinary tract sy- mptoms and who had not received medical or surgical treatment due to BPH (BPH group) and 52 healthy men (Control group) who did not have lower urinary tract symptoms and applied to the outpatient clinic for routine urological control. Vi- tamin D, total PSA, total testosterone values, IPSS scores, prostate volumes and maximum urinary velocity in uroflowmetry (Q max) of both groups were evaluated.

Results: The mean age of 48 patients with be- nign prostatic hyperplasia in BPH group was 65.37 ± 7.24 and in control group without urinary tract symptoms was 64.09 ± 8.22. There was a statistical- ly significant difference between BPH and control groups in terms of the mean values of 25 hydroxy vitamin-D values (p< 0.001). When the patients diagnosed with BPH were examined according to their subgroups; there was no statistically signifi- cant difference in terms of 25 hydroxy vitamin D levels between moderate LUTS (33 patients) and severe LUTS (15 patients) groups(p> 0.05).

Conclusion: Our study has shown that in patients with BPH and LUTS, 25 hydroxy vitamin D levels were lower than those in the similar age group without any complaints. Based on this, it was thought that there might be an improvement in the symptoms of patients with increasing vita- min D levels. To reach a final judgment on this subject, larger number of randomized controlled prospective studies are needed.

Keywords: Vitamin D, benign prostate hyperplasia, lower urinary tract symptoms
 

Abstract

Objective: We aimed to determine the relati- onship between vitamin D levels and benign pros- tate hyperplasia (BPH) related lower urinary tract symptoms (LUTS) in men over 40 years of age.

Material and Methods: The study was con- ducted prospectively between January and April 2019 and included 48 patients who presented to the outpatient clinic with lower urinary tract sy- mptoms and who had not received medical or surgical treatment due to BPH (BPH group) and 52 healthy men (Control group) who did not have lower urinary tract symptoms and applied to the outpatient clinic for routine urological control. Vi- tamin D, total PSA, total testosterone values, IPSS scores, prostate volumes and maximum urinary velocity in uroflowmetry (Q max) of both groups were evaluated.

Results: The mean age of 48 patients with be- nign prostatic hyperplasia in BPH group was 65.37 ± 7.24 and in control group without urinary tract symptoms was 64.09 ± 8.22. There was a statistical- ly significant difference between BPH and control groups in terms of the mean values of 25 hydroxy vitamin-D values (p< 0.001). When the patients diagnosed with BPH were examined according to their subgroups; there was no statistically signifi- cant difference in terms of 25 hydroxy vitamin D levels between moderate LUTS (33 patients) and severe LUTS (15 patients) groups(p> 0.05).

Conclusion: Our study has shown that in patients with BPH and LUTS, 25 hydroxy vitamin D levels were lower than those in the similar age group without any complaints. Based on this, it was thought that there might be an improvement in the symptoms of patients with increasing vita- min D levels. To reach a final judgment on this subject, larger number of randomized controlled prospective studies are needed.

Keywords: Vitamin D, benign prostate hyperplasia, lower urinary tract symptoms
 

Creative Commons

LİMRADIGITAL